Initially, NRF2 activation via GSK-3β inhibition was demonstrated for LiCl, a GSK-3β inhibitor used for the treatment of bipolar disorder and compound TDZD-8 [180], which is able to increased HO-1 expression. Here, GSK3B is linked to bipolar disorder.